(Q46840248)

English

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

0 references

0 references

invasive aspergillosis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

I I Raad

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

H A Hanna

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

M Boktour

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

Y Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

H A Torres

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

C Afif

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

D P Kontoyiannis

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

R Y Hachem

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

publication date

20 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

22

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

496-503

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

https://scigraph.springernature.com/pub.10.1038/sj.leu.2405065

0 references

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Aspergillosis. Pathogenesis, clinical manifestations, and therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Invasive aspergillosis in 2002: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Posaconazole: a broad-spectrum triazole antifungal

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

An epidemic of invasive fungal infection in a stem cell transplant unit; response to high-dose liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Lipid formulations of amphotericin B: recent progress and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

21 January 2018

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405065

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2405065

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18094720

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46840248&oldid=2134452006"